Onkologie. 2013:7(1):18-21

Bisphosphonates in urological malignancies

Jana Katolická
Onkologicko-chirurgické oddělení, FN u sv. Anny v Brně

The skeleton is a predilection site for metastasis of genitourinary tumours. If there is no treatment for bone disease, the majority of

patients with metastatic prostate cancer experience skeletal-related events (SREs) during the course of the disease, including pathological

fractures, spinal cord compression, the need for palliative radiotherapy, surgical procedures on the bones, cementoplasty, and

the presence of hypercalcaemia, that all reduce the quality of life and increase the mortality rate. The effect of various bisphosphonates

in treating bone metastases in prostate, bladder, and kidney cancers was assessed. The administration of zoledronic acid significantly

reduces the risk of developing SREs not only in prostate cancer, but also in kidney and bladder cancers.

Keywords: bisphosphonates, urological malignancies, skeletal-related events (SREs)

Published: February 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J. Bisphosphonates in urological malignancies. Onkologie. 2013;7(1):18-21.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Coleman RE. Metastatic bone dissease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165-176.
    2. Pavlík I. Podávání bisfosfonátů u pacientů s karcinomem prostaty metastazujícím do kostí. Farmakoterapie 2007; 4: 403-409.
    3. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 2005; 96: 964-969. Go to original source... Go to PubMed...
    4. Mulders PF, Abrahamsson PA, Bukowski RM. Burden of metastatic bone dissease from genitourinary malignancies. Expert Rev. Anticancer Ther 2010; 10(11): 1721-1733. Go to original source... Go to PubMed...
    5. Piga A, Bracci R, Ferretti B, et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumorspoorly responsive to chemotherapy. J. Exp. Clin Cancer Res. 1998; 17(2): 213-217.
    6. Heidenreich A, Elert A, Hoffmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002; 5: 231-235. Go to original source... Go to PubMed...
    7. Ernst DS, Tannock IF, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003; 21(17): 3335-3342. Go to original source... Go to PubMed...
    8. Small EJ, Smith MR, Seman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21: 4277-4284. Go to original source... Go to PubMed...
    9. Heidenreich A, Ohlmann C, Body JJ. Ibandronate in metastatic bone pain. Semin Oncol 2004; 31: 67-72. Go to original source... Go to PubMed...
    10. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patiens with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882. Go to original source... Go to PubMed...
    11. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98(5): 962-969. Go to original source... Go to PubMed...
    12. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21(23): 4277-4284. Go to original source... Go to PubMed...
    13. Hering F, Rodrigues PR, Lipay M. Clodronate for treatment of bone metastases in hormone refraktory prostate cancer. Int. Braz. J. Urol. 2003; 29(3): 228-233. Go to original source... Go to PubMed...
    14. Adami S, et al. Dichloromethylene diphosphonate in patiens with carcinoma of the prostate metastatic to the skeleton. J Urol 1985; 134: 1152-1154. Go to original source... Go to PubMed...
    15. Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidornate: results of randomised, prospective placebo controlled study. J Urol 1989; 141: 85-87. Go to original source... Go to PubMed...
    16. Vorreuther R. Bisphosphonates as an adjunct to palliative therapy in patiens with metastases from prostate carcinoma. A pilot study on clodronate. Br J Urol 1993; 72: 792-795. Go to original source... Go to PubMed...
    17. Kylmala T, et al. The effect of combined and oral clodronate on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol 1994; 83: 316-319. Go to PubMed...
    18. Cresswel S, et al. Pain relief and quality of life assessment following intravenous and oral clodronate in hormone escaped prostate cancer. Br J Urol 1995; 76: 360-365. Go to original source... Go to PubMed...
    19. Heidenreich A, et al. The use of bisphosphonates for paliative treatment of painful bone metastases due to hormone refractory prostate cancer. J Urol 2001; 165: 136-140. Go to original source... Go to PubMed...
    20. Saad F, Lipton A. Zoledronic acide is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 2005; 96(7): 964-969. Go to original source... Go to PubMed...
    21. Kijima T, FujiiY, Suyama T, et al. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU 2009; 103(5): 487-505. Go to original source... Go to PubMed...
    22. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol; 2010; 15(4): 382-389. Go to original source... Go to PubMed...
    23. Presto DM, et al. Androgen deprivation in men with prostate cancers associated with increased rate of bone loss. Prostate Cancer Prostatic Dis 2002; 5: 304-310. Go to original source... Go to PubMed...
    24. Shahinian VB, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164. Go to original source... Go to PubMed...
    25. Smith MR, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903. Go to original source... Go to PubMed...
    26. Coleman RE. Clinical features of metastatic bone dissease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243-6249. Go to original source... Go to PubMed...
    27. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals of Oncology, 2007.
    28. Bauss F, Body JJ. Ibandronate in metastatic bone dissease: a review of preclinical data. Anticancer Drugs 2005; 16: 107-118. Go to original source... Go to PubMed...
    29. Ullpen A, Lennartsson L, Hjelm-Eriksson M, et al. Additive/synergisti antitumoral effects on prostate cancer cells in vitro following treatment with combination of gemcitabine and zoledronic acid. Proc Am Soc Clin Oncol 2003; 22: 432(Abstr 1737).

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.